Karyopharm Therapeutics Inc (KPTI) Event Aug. 04, 2022, 00:00 UTC (42% Neutral) Karyopharm Therapeutics Inc. (KPTI) Reports Net Loss for 2022-06-30 Full text
Register to leave comments News bot Oct. 29, 2025, 11:51 a.m. 🏢 Karyopharm Therapeutics Inc (KPTI) - Form 10-Q Quarterly Report Quarterly financial filing submitted to the SEC 📋 Filing Information 📄 Form Type: 10-Q 📅 Filing Date: 2022-08-04 📊 Period of Report: 2022-06-30 ⏰ Accepted: N/A 📊 Key Financial Metrics (Period-over-Period Comparison) Metric Current Period Previous Period Change ($) Change (%) Trend Net Income/Loss $-111.00M $-111.00M N/A +0.00% ➡️ Total Assets $305.31M $256.48M $48.83M +19.04% 📈 Total Liabilities $384.98M $372.82M $12.16M +3.26% ↗️ Stockholders' Equity $-83.13M $-1.17B $1.08B +92.87% 📈 Operating Income/Loss $-101.42M $-77.49M $-23.93M -30.88% 📈 R&D Expense $71.03M $86.37M $-15.34M -17.76% 📈 SG&A Expense $74.18M $76.11M $-1.93M -2.53% ↘️ Earningspersharebasic $-1.48 $-1.15 $-0.33 -28.70% 📉 Earningspersharediluted $-1.48 $-1.15 $-0.33 -28.70% 📉 📈 Financial Trend Analysis 🔻 Reported net loss for the period • 🏦 Strengthened balance sheet with assets growing faster than liabilities 📎 View Full 10-Q Filing on SEC.gov Access the complete official filing document
🏢 Karyopharm Therapeutics Inc (KPTI) - Form 10-Q Quarterly Report
📋 Filing Information
Key Financial Metrics (Period-over-Period Comparison)
Financial Trend Analysis
🔻 Reported net loss for the period • 🏦 Strengthened balance sheet with assets growing faster than liabilities
📎 View Full 10-Q Filing on SEC.gov
Access the complete official filing document